Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Journal of the American College of Cardiology

Journal
uri icon
  • Overview
  • Identity
  • View All
scroll to property group menus

Overview

articles

  • Expanding the toolbox for reversal of anticoagulation in chronic kidney disease.  74:1769-1771. 2019
  • 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.  71:1021-1034. 2018
  • Myocardial infarction produces sustained proinflammatory endothelial activation in remote arteries.  72:1015-1026. 2018
  • Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release.  72:2040-2050. 2018
  • Using digital health technology to better generate evidence and deliver evidence-based care.  71:2680-2690. 2018
  • Interventions for increasing physical activity from "Ingenious Toys" to mHealth.  67:2464-2466. 2016
  • Moving from digitalization to digitization in cardiovascular care why is it important, and what could it mean for patients and providers?.  66:1489-1496. 2015
  • Genetic implication of a novel thiamine transporter in human hypertension.  63:1542-1555. 2014
  • Human heart rate: heritability of resting and stress values in twin pairs, and influence of genetic variation in the adrenergic pathway at a microribonucleic acid microRNA motif in the 3'-UTR of cytochrome b561.  63:358-368. 2014
  • RESPONSE: Time for the pager to enter retirement.  64:2705-2705. 2014
  • Influence of genetic polymorphisms on the effect of high-and standard-dose clopidogrel after percutaneous coronary intervention the gift (genotype information and functional testing) study.  59:1928-1937. 2012
  • Neuropeptide y (npy) genetic variation in the human promoter alters glucocorticoid signaling, yielding increased npy secretion and stress responses.  60:1678-1689. 2012
  • Association of mortality with years of education in patients with st-segment elevation myocardial infarction treated with fibrinolysis.  57:138-146. 2011
  • Common functional genetic variants in catecholamine storage vesicle protein promoter motifs interact to trigger systemic hypertension.  55:1463-1475. 2010
  • Neuropeptide y(1) receptor npy1r discovery of naturally occurring human genetic variants governing gene expression in cella as well as pleiotropic effects on autonomic activity and blood pressure in vivo.  54:944-954. 2009
  • The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.  54:1935-1945. 2009
  • Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.  52:1693-1701. 2008
  • Naturally occurring human genetic variation in the 3 '-untranslated region of the secretory protein chromogranin a is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion.  52:1468-1481. 2008
  • Platelet function monitoring in patients with coronary artery disease.  50:1822-1834. 2007
  • Future use of genomics in coronary artery disease.  50:1933-1940. 2007
  • In unstable angina or non-st-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting?.  49:849-854. 2007
  • Lack of evidence of a clopidogrel-statin interaction in the charisma trial.  50:291-295. 2007
  • Long-term outcome and its predictors among patients with st-segment elevation myocardial infarction complicated by shock: Insights from the gusto-i trial.  50:1752-1758. 2007
  • Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the charisma trial.  49:1982-1988. 2007
  • Redefining risk in acute coronary syndromes using molecular medicine.  49:279-289. 2007
  • Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.  47:155-162. 2006
  • Optimal timing for pre-treatment with before percutaneous the initiation of 300 mg clopidogrel coronary intervention.  47:939-943. 2006
  • The influence of peripheral arterial disease on outcomes - a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials.  48:1567-1572. 2006
  • Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention - results from the clopidogrel for the reduction of events during observation (credo) trial.  46:761-769. 2005
  • The genomic basis of myocardial infarction.  46:1456-1465. 2005
  • Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus - an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (replace)-2 trial.  45:1932-1938. 2005
  • Variability in platelet responsiveness to clopidogrel among 544 individuals.  45:246-251. 2005
  • Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.  44:2133-2136. 2004
  • Aspirin dose and six-month outcome after an acute coronary syndrome.  43:972-978. 2004
  • Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy.  43:1908-1914. 2004
  • Economic evaluation of bivalirudin with provisional glycoprotein iib/iiia inhibition versus heparin with routine glycoprotein iib/iiia inhibition for percutaneous coronary intervention - results from the replace-2 trial.  44:1792-1800. 2004
  • Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein iib/iiia blockade compared to heparin with routine glycoprotein iib/iiia blockade - a replace-2 substudy.  44:1194-1199. 2004
  • Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty.  43:936-942. 2004
  • Outcome of acute st-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein iib/iiia inhibition - lessons from the gusto v trial.  43:542-548. 2004
  • A guide to therapeutic decision-making in patients with non-st-segment elevation acute coronary syndromes.  41:123S-129S. 2003
  • A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.  41:961-965. 2003
  • Angiographic variables predict increased risk for adverse ischernic events after coronary stenting with glycoprotein iib/iiia inhibition - results from the target trial.  42:981-988. 2003
  • Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival - results from the do tirofiban and reopro give similar efficacy outcome trial (target).  42:1188-1195. 2003
  • Troponin and c-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome - a gusto-iv substudy.  41:916-924. 2003
  • Troponin t and quantitative st-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.  41:371-380. 2003
  • Association between ck-mb elevation after percutaneous or surgical revascularization and three-year mortality.  40:1961-1967. 2002
  • Early angioplasty in acute coronary syndromes without persistent st-segment elevation improves outcome but increases the need for six-month repeat revascularization - an analysis of the pursuit trial.  39:1924-1929. 2002
  • Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction - the integrilin and low-dose thrombolysis in acute myocardial infarction (intro ami) trial.  39:377-386. 2002
  • Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.  39:9-14. 2002
  • Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention.  40:669-675. 2002
  • Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability.  40:1034-1040. 2002
  • Prognostic significance of elevated troponin i after percutaneous coronary intervention.  39:1738-1744. 2002
  • The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes.  39:22-29. 2002
  • Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention.  37:2059-2065. 2001
  • Prevention of intimal hyperplasia with recombinant soluble p-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model.  38:577-582. 2001
  • Prognostic value of st segment depression in acute coronary syndromes: Insights from paragon-a applied to gusto-iib.  38:64-71. 2001
  • Reactivation of ischemic events in acute coronary syndromes: Results from gusto-iib.  37:1001-1007. 2001
  • Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes.  37:492-498. 2001
  • Abciximab reduces mortality in diabetics following percutaneous coronary intervention.  35:922-928. 2000
  • Application of a continuous regression model of restenosis to saphenous vein grafts after successful percutaneous transluminal coronary angioplasty or directional coronary atherectomy.  35:619-623. 2000
  • Clinical benefit of glycoprotein iib/iiia blockade with abciximab is independent of gender - pooled analysis from epic, epilog and epistent trials.  36:381-386. 2000
  • Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: Lessons from the gusto-iib angioplasty substudy.  35:1502-1512. 2000
  • Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus.  35:563-568. 2000
  • Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction - results from the speed (gusto-4 pilot) trial.  36:1489-1496. 2000
  • Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.  36:75-83. 2000
  • Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.  35:1103-1115. 2000
  • Platelet glycoprotein iib/iiia blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent st-segment elevation.  36:685-692. 2000
  • Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction.  35:136-143. 2000
  • Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention.  33:88-96. 1999
  • Comparing physician-specific two-year patient outcomes after coronary angiography - methodologic issues and results.  33:1278-1285. 1999
  • Effect of age on outcome with primary angioplasty versus thrombolysis.  33:412-419. 1999
  • Outcome of hispanic patients treated with thrombolytic therapy for acute myocardial infarction - results from the gusto-i and -iii trials.  34:1729-1737. 1999
  • The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics.  33:1269-1277. 1999
  • The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization - insights from the epic trial.  33:647-653. 1999
  • Acute myocardial infarction and complete bundle branch block at hospital admission: Clinical characteristics and outcome in the thrombolytic.  31:105-110. 1998
  • Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: The gusto-i experience.  32:634-640. 1998
  • Cost of cardiac care in the three years after coronary catheterization in a contained care system: Critical determinants and implications.  31:1306-1313. 1998
  • Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial.  31:31-36. 1998
  • Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment.  31:1466-1473. 1998
  • Heparin-induced thrombocytopenia.  31:1449-1459. 1998
  • Influence of a randomized clinical trial on practice by participating investigators: Lessons from the coronary angioplasty versus excisional atherectomy trial (caveat).  31:265-272. 1998
  • Modifiable risk factors for vascular access site complications in the impact ii trial of angioplasty with versus without eptifibatide.  31:1518-1524. 1998
  • Myonecrosis after revascularization procedures.  31:241-251. 1998
  • Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization.  32:311-319. 1998
  • Potential impact of evidence-based medicine in acute coronary syndromes: Insights from gusto-iib.  32:2023-2030. 1998
  • Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions.  32:936-941. 1998
  • Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the gusto-iib trial.  31:1493-1498. 1998
  • Recurrent ischemia after thrombolysis: Importance of associated clinical findings.  31:94-102. 1998
  • Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology.  32:1619-1623. 1998
  • The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-q-wave myocardial infarctions.  32:1366-1370. 1998
  • Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the gusto-i trial.  31:497-505. 1998
  • 28th Bethesda Conference. Task force 5: Assessment, approval, and regulation of new technology.  29:1171-1179. 1997
  • Atrial fibrillation in the setting of acute myocardial infarction: The gusto-i experience.  30:406-413. 1997
  • Coronary revascularization surgery after myocardial infarction: Impact of bypass surgery on survival after thrombolysis.  29:240-249. 1997
  • Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: Review of ocular hemorrhage incidence and location in the gusto-i trial.  30:1606-1610. 1997
  • Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein iib/iiia receptor blockade by abciximab (c7e3 fab) among patients with unstable angina undergoing percutaneous coronary revascularization.  30:149-156. 1997
  • Gender and acute myocardial infarction: Is there a different response to thrombolysis?.  29:35-42. 1997
  • Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction.  30:171-179. 1997
  • Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model.  29:808-816. 1997
  • Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: Observations from the gusto-i study.  30:708-715. 1997
  • Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The gusto-i experience.  28:1661-1669. 1996
  • Coronary artery stents.  28:782-794. 1996
  • Cost-efficacy modeling of catheter reuse for percutaneous transluminal coronary angioplasty.  28:106-111. 1996
  • Early discharge in the thrombolytic era: An analysis of criteria for uncomplicated infarction from the global utilization of streptokinase and t-pa for occluded coronary arteries (gusto) trial.  27:625-632. 1996
  • Effect of subintimal resection on initial outcome and restenosis for native coronary lesions and saphenous vein graft disease treated by directional coronary atherectomy - a report from the caveat i and ii investigators.  28:645-651. 1996
  • Increased risk of non-q wave myocardial infarction after directional atherectomy is platelet dependent: Evidence from the epic trial.  28:849-855. 1996
  • Late assessment of thrombolytic efficacy (late) study: Prognosis in patients with non-q wave myocardial infarction.  27:1327-1332. 1996
  • Prognostic significance of precordial st segment depression during inferior myocardial infarction in the thrombolytic era: Results in 16,521 patients.  28:305-312. 1996
  • Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions.  28:1111-1118. 1996
  • Role of platelets in restenosis after percutaneous coronary revascularization.  28:1643-1651. 1996
  • Selective inhibition of factor xa is more efficient than factor viia-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.  28:1858-1865. 1996
  • Time from symptom onset to treatment and outcomes after thrombolytic therapy.  27:1646-1655. 1996
  • Abrupt closure - the caveat-i experience.  26:1494-1500. 1995
  • Cardiac rupture associated with thrombolytic therapy - impact of time to treatment in the late assessment of thrombolytic efficacy (late) study.  25:1063-1068. 1995
  • Characteristics and consequences of myocardial-infarction after percutaneous coronary intervention - insights from the coronary angioplasty versus excisional atherectomy trial (caveat).  25:1693-1699. 1995
  • Contemporary reperfusion therapy for cardiogenic-shock - the gusto-i trial experience.  26:668-674. 1995
  • Directional atherectomy versus balloon angioplasty for coronary ostial and nonostial left anterior descending coronary-artery lesions - results from a randomized multicenter trial.  25:1380-1386. 1995
  • Evaluation of paradoxic beneficial-effects of smoking in patients receiving thrombolytic therapy for acute myocardial-infarction - mechanism of the smokers paradox from the gusto-i trial, with angiographic insights.  26:1222-1229. 1995
  • Lessons we have learned from the gusto trial.  25:S10-S17. 1995
  • Percutaneous revascularization of ostial saphenous-vein graft stenoses.  26:955-960. 1995
  • Peripheral vascular complications in the coronary angioplasty versus excisional atherectomy trial (caveat-i).  26:922-930. 1995
  • Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-1987 versus 1991 - improved in-hospital and 12-month results.  25:1137-1142. 1995
  • Treating menstruating women with thrombolytic therapy - insights from the global utilization of streptokinase and tissue-plasminogen activator for occluded coronary-arteries (gusto-i) trial.  26:1651-1656. 1995
  • Cardiac angiography without cine film - erecting a tower-of-babel in the cardiac-catheterization laboratory.  24:834-837. 1994
  • Cell-adhesion molecules in coronary-artery disease.  24:1591-1601. 1994
  • Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial-infarction.  23:891-898. 1994
  • Early angiography cannot predict postthrombolytic coronary reocclusion - observations from the gusto angiographic study.  24:1439-1444. 1994
  • Long-term angiographic and clinical outcome after implantation of a balloon-expandable stent in the native coronary circulation.  24:1207-1212. 1994
  • Pulmonary hemorrhage after intracoronary stent placement.  24:91-94. 1994
  • Randomized trials of directional coronary atherectomy - implications for clinical-practice and future investigation.  24:431-439. 1994
  • Balloon angioplasty for the treatment of lesions in saphenous-vein bypass grafts.  21:1539-1549. 1993
  • Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty - a matched case-control study.  21:866-875. 1993
  • Is traditionally defined complete revascularization needed for patients with multivessel disease treated by elective coronary angioplasty.  22:1289-1297. 1993
  • Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy.  21:597-603. 1993
  • Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty - clinical and angiographic outcomes.  22:135-143. 1993
  • Outcome of patients with diabetes-mellitus and acute myocardial-infarction treated with thrombolytic agents.  21:920-925. 1993
  • Thrombolytic therapy for women with myocardial-infarction - is there a gender-gap.  22:1780-1787. 1993
  • Thrombosis of a flexible coil coronary stent - frequency, predictors and clinical outcome.  21:622-627. 1993
  • Toward the quiescent coronary plaque.  22:1228-1241. 1993
  • Abrupt vessel closure after directional coronary atherectomy.  19:1372-1379. 1992
  • Abrupt vessel closure complicating coronary angioplasty - clinical, angiographic and therapeutic profile.  19:926-935. 1992
  • Accelerated plasminogen-activator dose regimens for coronary thrombolysis.  19:482-489. 1992
  • Cardiogenic-shock complicating acute myocardial-infarction - the use of coronary angioplasty and the integration of the new support devices into patient-management.  19:647-653. 1992
  • Confronting the issues of patient safety and investigator conflict-of-interest in an international clinical-trial of myocardial reperfusion.  19:1123-1128. 1992
  • Experimental-models of coronary-artery restenosis.  19:418-432. 1992
  • Intramural methotrexate therapy for the prevention of neointimal thickening after balloon angioplasty.  20:460-466. 1992
  • Mechanism of benefit of combination thrombolytic therapy for acute myocardial-infarction - a quantitative angiographic and hematologic study.  20:1305-1312. 1992
  • The restenosis paradigm revisited - an alternative proposal for cellular mechanisms.  20:1284-1293. 1992
  • A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen-activator therapy in acute myocardial-infarction.  17:467-473. 1991
  • Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomy.  18:1183-1189. 1991
  • Clinical-experience with the palmaz-schatz coronary stent.  17:B155-B159. 1991
  • Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions.  17:B126-B131. 1991
  • Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial-infarction.  18:1594-1601. 1991
  • Limitations of thrombolytic therapy for acute myocardial-infarction complicated by congestive-heart-failure and cardiogenic-shock.  18:1077-1084. 1991
  • Myocardial-infarction with minimal coronary atherosclerosis in the era of thrombolytic reperfusion.  17:304-312. 1991
  • Percutaneous support devices for high-risk or complicated coronary angioplasty.  17:770-780. 1991
  • Prospects for the use of antagonists to the platelet glycoprotein-IIb glycoprotein-IIIa receptor to prevent postangioplasty restenosis and thrombosis.  17:B89-B95. 1991
  • Treatment of recurrent ischemia after thrombolysis and successful reperfusion for acute myocardial-infarction - effect on in-hospital mortality and left-ventricular function.  17:752-757. 1991
  • Fate of patients with acute myocardial-infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty.  16:770-778. 1990
  • Initial report of the national-registry-of-elective-cardiopulmonary bypass supported coronary angioplasty.  15:23-29. 1990
  • Precordial st segment depression predicts a worse prognosis in inferior infarction despite reperfusion therapy.  16:1538-1544. 1990
  • Stroke and acute myocardial-infarction in the thrombolytic era - clinical correlates and long-term prognosis.  16:533-540. 1990
  • Combined tissue-type plasminogen-activator and prostacyclin therapy for acute myocardial-infarction.  14:877-884. 1989
  • Coronary angioplasty as primary therapy for acute myocardial-infarction 6 to 48 hours after symptom onset - report of an initial experience.  13:1122-1126. 1989
  • From myocardial salvage to patient salvage in acute myocardial-infarction - the role of reperfusion therapy.  14:1382-1388. 1989
  • Implications for patient triage from survival and left-ventricular functional recovery analyses in 500 patients treated with coronary angioplasty for acute myocardial-infarction.  13:1251-1259. 1989
  • Intracoronary stents - will they fulfill their promise as an adjunct to angioplasty.  13:1425-1430. 1989
  • Randomized, double-blind, placebo-controlled trial of tissue plasminogen-activator in unstable angina.  13:434-441. 1989
  • Reperfusion momentum - lessons from the randomized trials of immediate coronary angioplasty for myocardial-infarction.  14:1572-1578. 1989
  • Sudden paradoxic clinical deterioration during angioplasty of the occluded right coronary-artery in acute myocardial-infarction.  14:1202-1209. 1989
  • Thrombolysis and angioplasty in myocardial-infarction (tami-1) trial - influence of infarct location on arterial patency, left-ventricular function and mortality.  13:12-18. 1989
  • Cost and procedure implications of thrombolytic therapy for acute myocardial-infarction.  12:A58-A68. 1988
  • Emergency coronary-artery bypass-surgery preserves global and regional left-ventricular function after intravenous tissue plasminogen-activator therapy for acute myocardial-infarction.  11:899-907. 1988
  • Insights derived from the thrombolysis and angioplasty in myocardial-infarction (tami) trials.  12:A24-A31. 1988
  • Predictors of success for coronary angioplasty performed for acute myocardial-infarction.  12:1407-1415. 1988
  • A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen-activator (activase) in acute myocardial-infarction.  9:1205-1213. 1987
  • Community-hospital administration of intravenous tissue plasminogen-activator in acute myocardial-infarction - improved timing, thrombolytic efficacy and ventricular-function.  10:1173-1177. 1987
  • Multicenter study of percutaneous trans-luminal angioplasty for right coronary-artery ostial stenosis.  9:1214-1218. 1987
  • Thrombolysis and angioplasty in myocardial-infarction (tami) trial.  10:B65-B74. 1987
  • Doppler echocardiographic measurement of aortic-valve area in aortic-stenosis - a noninvasive application of the gorlin formula.  8:1059-1065. 1986
  • Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen-activator - importance of coronary angioplasty.  6:426-433. 1985
  • Thrombolysis with recombinant tissue plasminogen-activator in atherosclerotic thrombotic occlusion.  5:85-91. 1985
  • Immediate improvement of dysfunctional myocardial segments after coronary revascularization - detection by intraoperative trans-esophageal echocardiography.  4:1123-1134. 1984
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0735-1097

Electronic International Standard Serial Number (EISSN)

  • 1558-3597

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support